The DESolve Bioresorbable Coronary Scaffold is a novel drug-eluting device combining a PLLA-based scaffold coated with a bioresorbable polylactide-based polymer and the drug Myolimus. Myolimus, a macrocyclic lactone mTOR inhibitor, has demonstrated potent anti-proliferative properties in two First-in-Man (FIM) trials using Elixir's metallic coronary stents. The drug dose is 3 mcg per mm of scaffold length. We aimed to present the IVUS results of the first-in-man evaluation of this novel scaffold. Methods: The DESolve FIM trial enrolled 15 patients, treated with a single 3.0x14 mm DESolve at 3 centers. IVUS was performed at the end of the procedure and repeated at six-month invasive follow-up. Complete and adequate IVUS images at baseline and follow-up were obtained for 11 cases. Serial changes in vessel volume, scaffold area and the degree of NIH formation were assessed. All analyses were performed by an independent core laboratory. Results: From baseline to 6 months, IVUS showed a small increase in scaffold mean area (from 5.35 Ϯ 0.78 mm 2 to 5.61 Ϯ 0.81 mm 2 ). Additionally, there was no significant change in vessel volume (from 148.0 Ϯ 37.0 mm 3 to 150.03 Ϯ 35.38 mm 3 ) or area, demonstrating the absence of constrictive or expansive remodelling. There was very low neointimal volume (5.6 Ϯ 2.8 mm 3 ) and % scaffold obstruction (7.18 Ϯ 3.37%). and no cases of incomplete strut apposition.
Total number of matched SBs for analysis was 138, 72 in-stent and 66 in native vessels. Two SBs had kissing balloon dilatation and were grouped with jailed SBs. Analysis of the entire first millimeter was possible in 58% of analyzed SBs. Mean native ostial area was increased from 1.67Ϯ1.61 mm 2 at baseline to 1.74Ϯ1.85 mm 2 (pϭ0.44) at FU. Average in-stent ostial area was increased from 1.30Ϯ1.42 mm 2 at baseline to 1.52Ϯ1.54 mm 2 (pϭ0.06) at FU. In-stent ostial area gain between baseline and FU for Cypher was 0.32Ϯ1.00 mm 2 vs. 0.08Ϯ0.92 mm 2 (pϭ0.32) for Nobori. Neointimal bridging occurred in 13 (10%) of all assessed FU SBs. Intra-observer mean difference was 0.001Ϯ0.12 mm 2 and inter-observer mean difference was 0.012Ϯ0.23 mm 2 . Conclusions: Ostial SB evaluation by 3D reconstruction of main vessel OCT acquisition is feasible when the ostium is visible and can be performed with high intra-and interobserver agreement. DES-jailed SBs tended to improve in ostial MLA at 12-month FU while mean MLA in native SB ostia remained unchanged.
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Evaluation Serial (baseline and 6-month follow-up) OCT was available for 10 pts. All images were analyzed by an independent core laboratory at 0.6-mm interval. At baseline, scaffold malapposition and scaffold structural discontinuity (qualitatively defined as Ն 2 struts overhanging each other in the same angular sector of the lumen, or by isolated struts floating inside the lumen in complete misalignment with the surrounding struts) were assessed. At follow-up, serial changes in lumen and scaffold dimensions and degree of NIH formation on top of the struts were assessed. Frequency of covered struts and NIH thickness on top of each strut were also examined. Scaffold and strut malapposition were serially assessed at the cross-section and strut levels respectively. Results: At baseline, no signs of structural discontinuity were observed at the crosssection level inspection. Scaffold area was maintained over time with no evidence of scaffold recoil from baseline (6.57Ϯ0.68 mm 2 ) to follow-up (6.80Ϯ0.85 mm 2 , pϭ0.344). NIH area measured 0.71Ϯ0.36 mm 2 , with 13.16Ϯ5.59% obstruction of the scaffold area. At 6 months, 2,575 struts were analyzed and 98.7% were covered with a very thin NIH (0.12Ϯ0.04 mm). Scaffold malapposition was observed in only 1 cross-section of 1 scaffold. Rate of malapposed struts per scaffold varied from 2.01Ϯ2.75% to 0.04Ϯ0.12% over time (pϭ0.016).
Conclusions:
The DESolve Scaffold exhibited maintenance of its structural integrity upon deployment, proproviding excellent mechanical support without chronic recoil. At 6 months, it demonstrated effective NIH suppression without compromising tissue coverage of the polymeric struts,with virtually complete resolution of acute scaffold malapposition. Background: There are limited data about predictors of acute stent malapposition (ASM) and late persistent stent malapposition (LPSM) detected by optical coherence tomography (OCT). Methods: A total of 252 patients (257 lesions) who underwent both post-stent and follow-up OCT were enrolled for analysis. Malapposed struts on post-stent OCT were identified and those struts were re-evaluated on follow-up OCT. Various clinical, angiographic, and OCT parameters were evaluated to identify predictors of ASM and LPSM.
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Predictors Of Acute And Late Persistent Stent Malapposition After Percutaneous Coronary Intervention: A Follow-up Optical Coherence Tomography Study
Results: On post-stent OCT, 169 lesions (66%) showed ASM with malapposed strut % of 5.3 Ϯ 6.5. In univariate analysis, ASM lesion was associated with calcification, B2 or C lesion complexity, intra-coronary thrombus seen on OCT, post-balloon dissection, sirolimus-eluting stent (SES), and long stent length (Ն20 mm) more frequently than No-ASM lesion. However, only calcification (odds ratio [OR] ϭ 10.9; 95% confidence interval [CI], 1.3-92.0; p ϭ 0.029) and long stent length (Ն20 mm; OR ϭ 2.6; 95% CI, 1.1-6.6; p ϭ 0.042) were independent predictors of ASM in multivariate analysis. Of 169 ASM lesions, 55(33%) showed LPSM and 114(67%) showed resolved-ASM on follow-up OCT which was performed at 167 Ϯ 52 and 169 Ϯ 63 days after the index procedure, respectively (p ϭ 0.806). In univariate analysis, LPSM lesion showed higher frequency of SES, older patient age, higher baseline diameter stenosis %, higher malapposed strut % on post-stent OCT, and smaller neointimal thickness on follow-up OCT than resolved-ASM lesion. Patient age (Ͼ60 years) was the only independent predictor of LPSM in multivariate analysis (OR ϭ 3.7; 95% CI, 1.2-12.7; p ϭ 0.042). Uncovered strut % on follow-up OCT was higher in LPSM lesion than resolved-ASM lesion (30% vs. 10%, p Ͻ0.001). However, there were no significant differences of major adverse cardiac events between LPSM and resolved-ASM lesion during 2-year follow-up (3.6% vs 2.6%, respectively, p ϭ 0.661).
Conclusions:
In this OCT study, calcification and long stent length were the independent predictors of ASM. The predictor of LPSM was patient age. LPSM was not associated with increased risk of clinical events.
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Neoatherosclerosis Background: Manufacturer-predicted stent expansion is based on in-vitro testing. Actual expansion is related to stent architecture, lesion characteristics, etc. We evaluated the relationships between these variables on coronary DES expansion via IVUS. Methods: 1,652 IVUS frames were acquired and blindly analyzed in 56 lesions post-DES via Volcano EagleEye Platinum 20 MHz IVUS. DES studied were Medtronic Endeavor (nϭ32, 666 mm) and Resolute (nϭ12, 266 mm), and Abbott Xience V (nϭ12, 215 mm) deployed at 16-22 ATM after nominal balloon pre-dilatation. Expansion deficit (ED, %) was the ratio of observed to predicted average stented diameter. Results: DES were less expanded than predicted (ED ϭ -10.5%, pϽ0.001) but none evidenced malapposition after high-pressure deployment. Mean ED was highest in Endeavor vs. Xience or Resolute (-11.8% vs. -6.0% vs. -10.6%, pϽ0.001, Fig 1) 
